Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
(AKS - Get Report)
downgraded at Goldman from Buy to Neutral. Company is facing higher input costs.
(BKE - Get Report)
upgraded at Goldman from Sell to Neutral. $28 price target. Fashion cycle is easing for the company.
Corrections Corp of America
(CXW - Get Report)
downgraded at Barclays to Equal Weight from Overweight. Minimal margin improvement opportunities. Price target raised by a dollar to $28.
downgraded at BMO from Outperform to Market Perform. Valuation call, based on a $38 price target.
Research in Motion
downgraded at Kaufman from Buy to Hold. $60 price target. Company is facing increased competition.
rated new Outperform at BMO. Coverage of ROVI was started with an Outperform rating. $60 price target. Growth should accelerate as its content and reach expands.
upgraded at Goldman from Neutral to Buy. Company has exposure to growth in the aerospace and energy markets.
(SGEN - Get Report)
rated new Overweight at Piper Jaffray. $20 price target. Company is on the verge of bringing its first drug to market.
upgraded at ISI from Hold to Buy. $22 price target. Company is executing better and is a potential takeover target.
downgraded at Credit Suisse to Neutral from Outperform. Valuation call. Maintain $30 price target.
rated new Outperform at Wells Fargo. Rail supply industry appears to be at the beginning of a multi-year recovery.
rated new Overweight at Piper Jaffray. $20 price target. HAE drug should ultimately be able to generate $500 million of annual U.S. sales.